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Aims
 
To describe the pharmacokinetic–pharmacodynamic (PK–PD) characteristics of the
direct thrombin inhibitor dabigatran in hip replacement patients by assessing coagu-
lation parameters activated partial thromboplastin time (aPTT) and ecarin clotting
time (ECT), interindividual variability and factors affecting PD responses.
 
Methods
 
BISTRO I patients received oral dabigatran etexilate postsurgery for 6–10 days. Dabig-
atran plasma concentrations and aPTT/ECT were measured on the day of surgery, on
subsequent days and at steady state. PK–PD characteristics of the dabigatran–aPTT/
ECT relationships were evaluated using NONMEM V.
 
Results
 
The dabigatran concentration–aPTT relationship was described combining a linear
and an 
 
E
 
max
 
 model. Mean baseline aPTT was 33.4 s and 
 
E
 
max
 
 (maximum increase in
aPTT contributed by the 
 
E
 
max
 
 model) was 26.9 s. The dabigatran concentration needed
to attain 50% of maximum effect (EC
 
50
 
) was 94.7 ng ml
 
−
 
1
 
 and the mean slope of
the linear concentration–response relationship (SLOP) was 0.0509 s ng
 
−
 
1
 
 ml
 
−
 
1
 
. Base-
line aPTT and 
 
E
 
max
 
 were highest following surgery and declined with time. The
dabigatran concentration–ECT relationship fitted a linear model. Mean baseline ECT
was 28 s and decreased with time; 50% of the maximum effect was observed after
2.9 days. SLOP decreased from 0.38 to 0.27 s ng
 
−
 
1
 
 ml
 
−
 
1
 
 with a half-life of 1.1 day,
indicating greater PD effects on the day of surgery. Interindividual and residual
variability was low. Covariates could not explain variability of this model.
 
Conclusions
 
aPTT and ECT prolongation were directly correlated with dabigatran concentrations.
Blood coagulation prolongation was most pronounced following surgery. Data suggest
that ECT provides a more precise description of the anticoagulant effect than aPTT.
 
Introduction
 
Thrombin, a trypsin-like serine protease, plays a central
role in the processes of thrombosis and haemostasis. It
is a key enzyme in the blood coagulation cascade, exhib-
iting both pro- and anticoagulant properties, and a major
factor in the initiation and propagation of thrombotic
disease through the catalysis of fibrin formation from
fibrinogen and by stimulating platelet aggregation. It
also activates coagulation factors V, VIII, XI and XIII of
the coagulation cascade. Given the key role of thrombin
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in thrombotic events, thrombin inhibition represents a
therapeutic target for numerous thromboembolic dis-
eases [1, 2].
Dabigatran etexilate (Boehringer Ingelheim Pharma,
Ingelheim, Germany) is the orally available prodrug of
dabigatran, a synthetic, direct, reversible inhibitor of
thrombin. The active principal, dabigatran, selectively
inhibits thrombin with a 
 
K
 
i
 
 of 4.5 n
 
M
 
 and has been
shown to exhibit potent anticoagulant and antithrom-
botic activities in a number of animal models of throm-
bosis [3, 4]. The prodrug, dabigatran etexilate, is rapidly
and completely converted to the active principal dabig-
atran by hydrolysis catalysed by unspecific, ubiquitous
esterases [2]. No specific enzymes, e.g. CYP450 reduc-
tases, are involved in dabigatran etexilate prodrug
conversion.
Dabigatran etexilate is under development as an
orally active anticoagulant for the prevention and treat-
ment of thromboembolic events. Dabigatran etexilate
has been administered to healthy male subjects in a
series of Phase I clinical studies [5–7]. The linear phar-
macokinetic (PK) profile of dabigatran is characterized
by maximum plasma concentrations reached within 2 h
after administration and by a bi-exponential disposition
and elimination phase. The terminal half-life is 14–17 h
after multiple-dose administration; steady state is
achieved on the third day of twice-daily (bid) treatment.
The drug is mainly eliminated unchanged by renal
excretion; after intravenous administration of dabigat-
ran, urinary recovery amounts to approximately 80% of
the dose. Dabigatran is not metabolized by cytochrome
P450 isoenzymes. Small concentrations of pharmacody-
namically active dabigatran glucuronide conjugates are
present in plasma. The concentrations of the acylglucu-
ronides were quantified in plasma samples from several
clinical studies and were in the range of 7–24% of total
dabigatran in plasma. Absolute bioavailability of dabig-
atran administered as the prodrug, dabigatran etexilate,
is about 5%. The interindividual variability in elderly
healthy subjects was shown to be low. Interindividual
coefficients of variation (CV) of the maximum plasma
concentrations and area under the plasma concentra-
tion–time curves were usually 
 
<
 
30%. The within-
subject variability was very low (6–14% CV) [7]. In
orthopaedic patients, interindividual variability of PK
parameters were high, with CVs 
 
>
 
60% [8]. The
increased variability of dabigatran pharmacokinetics in
orthopaedic patients might be rationalized by surgical
effects on drug absorption, comedications, e.g. opioids
causing gastroparesis, and higher variations in patients’
kidney function.
In healthy volunteers, close correlations have been
observed between dabigatran plasma concentrations and
blood coagulation times, as assessed by prolonged acti-
vated partial thromboplastin time (aPTT), ecarin clot-
ting time (ECT), thrombin time (TT) and prothrombin
time [expressed as International Normalized Ratio
(INR)] [5, 6]. Toxicology studies have shown that bleed-
ing is the dose-limiting event without specific target
organ toxicity.
A dose-finding Phase IIa study (BISTRO I) [9] has
been performed to determine the safe therapeutic range
for dabigatran etexilate following total hip or knee
replacement surgery. In this multicentre, open-label,
dose-escalating study, patients received oral doses of
dabigatran etexilate [12.5, 25, 50, 100, 150, 200 or
300 mg bid, or 150 mg or 300 mg once daily (qd)] for
6–10 days after surgery. All patients in a given dose
group received only that dose of study medication. Pri-
mary efficacy outcomes included venographic deep vein
thrombosis (DVT), symptomatic DVT and pulmonary
embolism during the treatment period; the primary
safety outcome was major bleeding. The overall inci-
dence of DVT was 12.4% (28/225 patients) and there
was no consistent relationship between dabigatran dose
and incidence of DVT; the highest incidence of DVT in
any patient subgroup was 20.8% (5/24 patients) in the
12.5-mg dose group. No major bleeding events were
observed in any group; however, two patients with
reduced renal function receiving the highest dose
(300 mg bid) suffered bleeding from multiple sites asso-
ciated with prolonged pharmacodynamic (PD) effects.
A dose–response was demonstrated for all major and
minor bleeding events.
The BISTRO I study indicated that dabigatran etexi-
late demonstrates an acceptable safety profile when
administered within the therapeutic range (12.5–300 mg
bid). Furthermore, the low number of venous throm-
boembolic (VTE) events within each treatment group
indicates a satisfactory antithrombotic potential,
although the BISTRO I study was not powered to deter-
mine efficacy [9]. Oral administration of dabigatran
etexilate, commenced early in the postoperative period,
was shown to be effective and safe across a range of
doses in 1949 patients treated in the BISTRO II study
[10].
The primary objective of the current population PD
analysis was to describe the PK–PD characteristics of
dabigatran in patients undergoing elective hip replace-
ment surgery in the BISTRO I study by assessing the
blood coagulation parameters, aPTT and ECT. The anal-
ysis also aimed to investigate the effects of patient
demographics (age, weight, gender, creatinine clear-
ance) and treatment effects (e.g. fed/fasted condition,
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concomitant medications) on PD model parameters.
Inter- and intraindividual variability in blood coa-
gulation parameters in orthopaedic patients were also
studied.
 
Methods
 
Study design
 
Data were obtained from the multicentre, open-label,
dose-escalation study, BISTRO I [8]. In the study, 289
patients received dabigatran etexilate orally at doses of
12.5, 25, 50, 100, 150, 200 or 300 mg bid, or 150 mg or
300 mg qd. The first dose was administered 4–8 h after
total hip replacement surgery and dosing was continued
for 6–10 days. Between 20 and 46 patients were treated
in each of the nine dosing subgroups (Table 1). Of the
289 patients, 262 completed the study and 27 discontin-
ued treatment prior to study completion. Available data
from these 27 patients were included in the analysis.
Two patients for whom plasma concentration values
were not available were excluded. The protocol was
approved by National Ethics Committees and written
informed consent was obtained from all patients prior
to inclusion.
 
Sample collection
 
Dabigatran plasma concentrations and aPTT and ECT
values were measured at the following approximate time
points in patients in each dosage subgroup: before and
4 h after the first dose of dabigatran on the day of sur-
gery; before drug administration and 2 h after each dose
on subsequent days; and by frequent sampling at steady
state – usually on day 4 after surgery. Blood samples
were collected predose within 2–4, 4–8 and 8–12 h after
drug administration. In a subpopulation of 21 patients,
a more conventional PK–PD sampling was also per-
formed, in which seven blood samples were collected
predose and at 0.5, 1, 2, 4, 8 and 12 h after administra-
tion of the morning dose on day 4.
 
Determination of plasma dabigatran concentrations
 
Total concentrations of dabigatran in plasma represent-
ing free, nonconjugated dabigatran and dabigatran
released after alkaline cleavage of dabigatran conjugates
were determined.
Quantitative measurement of plasma dabigatran con-
centrations was performed using a liquid chromatogra-
phy-tandem mass spectroscopy (LC-MS/MS) method.
Eighty-microlitre sample volumes of patient plasma
were analysed using a Sciex API 3000 (PerkinElmer,
Boston, MA, USA) LC-MS/MS system. An electro-
spray ion source with atmospheric pressure ionization
was used for measurements performed in the positive
ionization mode. Separation was achieved by direct
injection onto a precolumn and subsequent transfer by
column switching onto a high-performance liquid chro-
matography (HPLC) column. Monitored ions were
 
Table 1
 
Baseline characteristics of all patients receiving dabigatran treatment within the nine dosage subgroups following total hip 
replacement surgery in BISTRO I
 
Characteristic
 
N
 
*
Dose of dabigatran etexilate (mg)
12.5
bid
27
25
bid
28
50
bid
30
100
bid
40
150
bid
29
200
bid
28
300
bid
20
150
qd
41
300
qd
46
All
289
 
Age (years)
 
Mean 68 65 67 67 67 67 70 66 67 67
Range 50–88 35–85 52–86 45–80 49–79 55–82 47–82 44–82 50–84 35–88
 
Weight (kg)
 
Mean 78 80 76 80 81 76 75 80 77 78
Range 58–130 49–117 54–102 55–127 57–120 55–106 56–128 53–105 50–109 49–130
 
Female sex
 
Number 11 12 17 24 12 16 14 20 26 152
Percentage 40.7 42.9 56.7 60.0 41.4 57.1 70.0 48.8 56.5 52.6
 
BMI (kg m
 
−
 
2
 
)
 
Mean 26 27 26 28 27 26 26 27 27 27
Range 22–36 19–37 21–31 21–40 21–39 21–32 21–40 20–34 18–36 18–40
*
 
N, Number of patients receiving surgery and dabigatran treatment within each treatment group; BMI, body mass index.
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472.2
 
→
 
289.5 (dabigatran), 478.2
 
→
 
295.6 (internal stan-
dard) and 648.2
 
→
 
288.9 (dabigatran glucuronide). The
lower limit of quantification (LOQ) was 1.0 ng ml
 
−
 
1
 
.
The linearity of the method, i.e. the mean correlation
coefficient of the standard curves, was 0.99953. At the
lower limit of quantification, the precision of the anal-
ytical method was 6.67% CV and accuracy (bias) was
 
−
 
2.66%.
Sample stability was demonstrated for at least
6 months at 
 
−
 
20 
 
°
 
C. Samples were shipped from study
sites on a regular basis for continuous analysis during
the study term.
 
APTT and ECT analysis of plasma samples
 
aPTT and ECT values were determined in two separate
central laboratories, according to Good Laboratory
Practice regulations. Blood samples were drawn in cit-
rated tubes and plasma was separated. ECT was mea-
sured using a Biomatic B10 coagulometer (Desaga,
Wiesloch, Germany) in a central laboratory and aPTT
was measured in a second central laboratory employing
an STA Compact coagulation analyser (Roche Diagnos-
tics, Basel, Switzerland).
 
Data analysis
 
aPTT and ECT data were fitted separately. All the anal-
yses were performed under the population modelling
approach with NONMEM version V using the First
Order Conditional Estimation (FOCE) method [11, 12],
in accordance with the recommendations on population
PK analysis from the Food and Drug Administration
[13]. Interindividual variability was modelled exponen-
tially and a proportional error model was used to
account for the residual variability.
Model selection was based on the visual inspection
of the goodness-of-fit plots and the precision of model
parameter estimates. The minimum value of the objec-
tive function (MOFV) provided by NONMEM was also
used as a guide during the model-building process. A
decrease in MOFV of 3.84 and 10.83 points between
two nested models is significant at the 5 and 0.1% levels,
respectively.
 
Population model development
 
As a first step, a model describing the data adequately
without incorporating covariates (basic population
model) was selected. A preliminary exploration of the
observed effects (aPTT and ECT) 
 
vs.
 
 the observed total
(conjugated plus unconjugated) dabigatran concentra-
tions in plasma (
 
C
 
) revealed that counter-clockwise or
clockwise hysteresis loops were not present in the data,
suggesting a direct relationship between drug in plasma
and response (see Figures 1, 4 and 5). Such a direct
relationship has been observed in the past for two other
oral thrombin inhibitors, inogatran and melagatran [14,
15, 16].
The PD profiles shown in Figure 1 suggest that the
relationship between aPTT and dabigatran in plasma can
be described with a combination of a linear and an 
 
E
 
max
 
model, as was the case for inogatran [14].
 1
 
E
 
0
 
 is aPTT at baseline; 
 
E
 
max
 
 and EC
 
50
 
 are the maximum
increase in aPTT and the dabigatran plasma concentra-
tion eliciting half of 
 
E
 
max
 
 corresponding to the nonlinear
part of the model, respectively. SLOP is the slope of the
linear relationship.
In Figures 4 and 5, the ECT 
 
vs.
 
 dabigatran in plasma
data show a linear profile:
 2
 
E
 
0
 
 in Equation 2 is ECT at baseline and SLOP is the
slope of the linear relationship.
Other models, such as the sigmoidal 
 
E
 
max
 
 and power
models, were also fitted to the data. Since dabigatran
was administered during a 2-week period, the possibility
of time effects on the PD model parameters was also
investigated. For this purpose, linear 
 
E
 
max
 
 or exponential
models were used.
The general additive modelling (GAM) [17] approach
was performed with S-PLUS using the Xpose [18] pro-
aPTT E E C
EC C
SLOP C= + ¥
+
+ ¥0
50
max
ECT E SLOP C= + ¥0
 
Figure 1 
 
Activated partial thromboplastin time (aPTT) values (s) with increasing 
dabigatran plasma concentrations (ng ml
 
−
 
1
 
) in individual patients 
following administration of dabigatran etexilate on day 4 (steady 
 
state) following orthopaedic surgery in BISTRO I
Dabigatran plasma concentration [ng/mL]
0 200 400 600 800 1000
aP
T
T
 [
s]
15
30
45
60
75
90
105
120
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gram to preselect potential covariates. The Akaike infor-
mation criterion is the selection criterion of this GAM
approach. Covariates selected during the GAM
approach were evaluated individually in NONMEM and
those that showed significance on a level of 
 
P
 
 
 
=
 
 0.05
were then tested and incorporated one at a time until the
full covariate model was obtained (forward inclusion).
Following the forward inclusion, a backward elimina-
tion was then performed on a significance level of
 
P
 
 
 
=
 
 0.001.
The selected model was validated internally [13]
computing the bias and precision in the model parame-
ters and simulated response values obtained from 100
datasets, including the same study design characteristics
of the original data and simulated data based on the
fixed- and random-effect parameters estimated in the
selected model. The median performance error (MPE)
and the median of the absolute performance error
(MAPE) were calculated and used as a measure of bias
and precision, respectively.
 
Results
 
Patient demographics
 
In total, 4854 parallel PK and PD observations were
employed for the development of the aPTT model and
5060 observations were employed for the ECT model.
The performance of these observations yielded approx-
imately 17 samples per patient for the 287 patients
included in the analysis. Both patients and PK–PD
observations were uniformly distributed across the nine
dosage groups. The greatest proportion of samples
(23%) was collected at steady state on day 4; only 2.7%
of the samples were taken after day 7. Demographic data
from the study subjects, according to dosage subgroup,
are shown in Table 1.
 
APTT model
 
Overall, the prolongation of aPTT increased in a non-
linear manner with increasing concentrations of dabig-
atran (Figure 1). A combined 
 
E
 
max
 
 and linear model
(Equation 1) best describes the relationship between
dabigatran plasma concentration (
 
C
 
) and aPTT at steady
state (depicted by a solid line in Figure 1).
Figure 2 shows the contributions of both the linear
and nonlinear parts of the dabigatran plasma concentra-
tion–aPTT relationship to the overall PK–PD response.
Up to a dabigatran plasma concentration of approxi-
mately 200 ng ml
 
−
 
1
 
, the PK–PD response was domi-
nated by the nonlinear, 
 
E
 
max
 
-type correlation, whereas at
higher dabigatran concentrations the PK–PD relation-
ship became linear. The resulting combined 
 
E
 
max
 
 and
linear model provided a good fit for the patient data
(Figure 1, open symbols). 
 
E
 
0
 
 and 
 
E
 
max
 
 were found to be
dependent on the amount of time elapsed after surgery.
Decreases in 
 
E
 
0
 
 and 
 
E
 
max
 
 values over time (
 
T
 
) were
modelled using proportional inhibitory models:
 
3
 4
In the first model, BAS
 
0
 
 represents the 
 
E
 
0
 
 value at time
0 (the time of the first administration of dabigatran etex-
ilate) on the day of surgery, EMBA is the maximum
decrease in E0, and ET50 is the time point at which E0
decreases by 50%. In the latter model, EMAO represents
the initial Emax value at time 0, EMMX is the maximum
decrease in Emax, and ET50 is the time point at which Emax
decreases by 50%.
Figure 3 shows the change over time after surgery in
the maximum aPTT response. The initial Emax of 26.9 s
at the time of surgery diminished with a half-life of
1.62 days. At an infinite time after surgery, the maxi-
mum prolongation of aPTT contributed by the sigmoidal
part of the concentration–aPTT relationship was esti-
mated to be 14.4 s, representing a 46% decrease in Emax
(Table 2).
The dabigatran plasma concentration required to
achieve 50% of the maximum effect, EC50, was
94.7 ng ml−1. Baseline aPTT (33.4 s) showed a similar
E BAS EM T
ET To BA0 50
1= ¥ - ¥
+
È
ÎÍ
˘
˚˙
E EMA EM T
ET To MXmax
= ¥ - ¥
+
È
ÎÍ
˘
˚˙
1
50
Figure 2 
Contributions of the Emax-type (nonlinear) and linear parts of the dabigatran 
plasma concentration–activated partial thromboplastin time (aPTT) 
relationship to overall pharmacokinetic–pharmacodynamic responses in 
the treated patient population at time 0 (time of administration of the first 
dose) on the day of surgery in BISTRO I. Linear and Emax + baseline 
(——), linear part + baseline (– –), Emax part + baseline (- - -)
0 200 400 600 800 1000
Dabigatran plasma concentration [ng/mL]
aP
T
T
 [
s]
30
40
50
60
70
80
90
100
110
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decline over time, with 50% of the maximum effect
observed after 1.62 days and a baseline value of 30.0 s
estimated at an infinite time after surgery. Parameter
estimates from the concentration–aPTT response model
based on the treated patient population, together with
standard error and interindividual variability calcula-
tions, are provided in Table 2.
A covariate analysis was performed in order to iden-
tify patient or treatment variables that might influence
the aPTT and ECT responses. The major covariates
included comedications (e.g. diuretics, opioids, nonste-
roidal anti-inflammatory drugs, drugs accelerating the
gastrointestinal transit time, acetaminophen, cyto-
chrome 3A4 inhibitors), patient demographics (gender,
age, height, body mass index) and standard clinical lab-
oratory parameters. None of the covariates exhibited
relevant effects on any of the aPTT model parameters.
ECT model
A linear model adequately described the relationship
between dabigatran plasma concentration and prolonga-
tion of ECT (Equation 2).
In contrast to the aPTT model, there was a simple
linear relationship between dabigatran plasma concen-
tration and the prolongation of ECT. However, due to
mis-specifications observed in the goodness-of-fit plots
during early model development, it was found that the
slope of the line of regression varied with time after
surgery. To illustrate this effect, the ECT/dabigatran
plasma concentration dataset can be separated into data
obtained within 12 h after surgery and data obtained at
100 h after surgery.
Early data revealed a steeper slope of the regression
line compared with late data (>100 h) indicating greater
sensitivity in the ECT response shortly after surgery
(Figures 4 and 5). The exponential decay in SLOP from
Figure 3 
Changes in Emax over time in patients receiving dabigatran etexilate 
following orthopaedic surgery based on calculations from the 
concentration–response model for activated partial thromboplastin 
time
Time (hrs)
0 50 100 150 200 250
E
M
A
X
 [
s]
14
17
20
23
26
29
EMAXmax = 26.9
EMAX50 = 20.7
EMAXtz = 14.4
ET50 = 38.9 [h] or 1.62 [days]
Table 2
Mean estimates, standard error, interindividual variability and descriptions of component parameters in the activated partial 
thromboplastin time (aPTT) concentration–response model based on data from the BISTRO I patient population
Parameter
Parameter
estimate
RSE
(%)*
IIV
(%)†
RSE of
IIV (%)* Description
BAS0 (s) 33.4 0.63 8.7‡ 10.51§ Baseline aPTT at time 0 on the day of surgery
EMA0 (s) 26.9 12.45 19.9‡ 33.92§ Emax at time 0 on the day of surgery
EMBA 0.102 14.41 NE NE Constant describing the maximum decrease in baseline aPTT over time
EC50 (ng ml−1) 94.7 17.11 38.5 40.41§ Plasma concentration at which the effect of the non linear part of the model 
is 50% that of Emax
SLOP (s ng−1 ml−1) 0.0509 6.68 15.2 45.22§ Constant describing the slope of the linear part of the line of regression
EMMX 0.463 12.68 NE NE Constant describing the maximum decrease in Emax over time
ET50 (days) 1.62 15.99 NE NE Time point at which baseline aPTT and Emax decreases by 50% and the effect 
is half that of EMBA and EMMX
Residual error (σ) 7.55* 3.53 NE NE Proportional error reported as coefficient of variation (CV %)
*RSE, Residual standard error. Percentage standard error for the parameter estimates was calculated according to percentage
RSE: 100% · SE/parameter estimate. †IIV, Inter-patient variability. Estimates of variance components (ω and σ) were converted
into standard deviations by taking their square root. These are reported as coefficients of variation (% CV) after multiplying
them by 100. ‡Interpatient variability is based on values for E0 and Emax rather than BAS0 (initial E0 at time 0) or EMA0 (initial
Emax at time 0). §Percentage SE is given on the variance scale; NE, not estimated.
Effects of dabigatran during total hip replacement
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time zero to infinity (Figure 6) was modelled by com-
bining two exponential terms:
SLOP = SLO0 × e(−KM × TIME) + SLOF 
× (1 − e(−KM × TIME)) 5
SLO0 is the initial slope value at time 0 (time of first
administration, usually on the day of surgery), SLOF is
the final slope value at time infinity, and KM describes
the rate of decrease in the slope which can be expressed
as a half-life with a value of 27 h. The initial slope of
0.377 s ng−1 ml−1 decreased to 0.268 s ng−1 ml−1 at time
infinity. Immediately after surgery, a 10 ng ml−1 increase
in dabigatran plasma concentrations prolonged the ECT
by 3.8 s, whereas at later time points (e.g. >5 days after
surgery), the same dabigatran concentrations increased
the ECT by 2.7 s (Figure 6).
As with aPTT, baseline ECT was found to vary with
time after surgery, and again, the change in baseline over
time was successfully modelled using a proportional
inhibitory Emax model, equal to the one used in the case
of aPTT responses (Equation 3).
Baseline ECT decreased from 28 s at the time of
surgery to 23.1 s with half the maximum effect at
2.9 days after surgery. Parameter estimates obtained
with the final ECT model are summarized in Table 3.
As with aPTT, covariate analysis revealed that none
of the investigated covariates (comedications, patient
demographics, serum creatinine clearance, standard
clinical laboratory parameters) exerted relevant effects
on any of the model parameters.
Figure 4 
The relationship between patient ecarin clotting time (ECT) values and 
dabigatran plasma concentrations 0–12 h after first administration of 
dabigatran etexilate following orthopaedic surgery. Individual patient ECT 
values are indicated by empty squares. The dashed black line represents 
the fit of the linear ECT model to the early (0–12 h post surgery) data; 
the solid grey line represents the fit of the model to the late (>100 h post 
surgery) data. SLOP and BASE at time 0 h (- - -), individual values ≤ 12 h 
(), SLOP and BASE at time 150 h (——)
Dabigatran plasma concentration [ng/mL]
0 50 100 150 200 250 300 350
E
C
T
 [
s]
20
40
60
80
100
120
140
160
Figure 5 
The relationship between patient ecarin clotting time (ECT) values and 
dabigatran plasma concentrations >100 h after first administration of 
dabigatran etexilate (steady state) following orthopaedic surgery. Individual 
patient ECT values are indicated by empty squares. The dashed black line 
represents the fit of the linear ECT model to the early (0–12 h post surgery) 
data; the solid grey line represents the fit of the model to the late (>100 h 
post surgery) data. SLOP and BASE at time 0 h (- - -), individual 
values > 100 h (), SLOP and BASE at time 150 h (——)
Dabigatran plasma concentration [ng/mL]
0 200 400 600 800 1000
E
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T
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20
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320
Figure 6 
Change over time after surgery in SLOP – the slope of the linear part of 
the equation describing the relationship between dabigatran plasma 
concentration and prolongation of ecarin clotting time (ECT). The effect of 
dabigatran administration on ECT prolongation was greatest shortly after 
surgery and declined with time
Time (hrs)
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SLOPmax = 0.377
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Model validation
The MPE for fixed effects in the aPTT model ranged
from −4.8% to 0.8%, while the MPE for random effects
was in the range −12.50 to 6.33%, indicating that the
aPTT values predicted by the model were accurate. The
MAPE for fixed effects ranged between 0.6% and
11.7%, with the MAPE for random effects ranging
between 6.2% and 31.7%. MPE and MAPE values
from the ECT model were much smaller than those
from the aPTT model. Bias and imprecision of the
aPTT values were 0.9% and 11.6%, respectively,
while those of the ECT values were 0.8% and 9.9%,
respectively.
Discussion
aPTT is a commonly used tool for measuring the degree
of anticoagulation in patients receiving anticoagulant
medications. It has long been used to monitor treatment
with heparin [19] and has been employed more recently
in the clinical evaluation of direct thrombin inhibitors
(DTIs), such as hirudin, hirulog, argatroban, inogatran
and melagatran [20–26]. Therapeutic ranges for aPTT
have been established empirically for heparin in various
indications [27], but difficulties exist in the useful appli-
cation of such ranges due to a lack of standardization in
measurement methods between laboratories.
ECT is a biomarker that is being used increasingly to
measure levels of anticoagulation [28, 29]. ECT offers
some advantages in comparison with aPTT due to its
higher sensitivity and its linearity even at high plasma
concentrations.
In the BISTRO I dose-escalation study [8], plasma
concentrations of the oral DTI dabigatran etexilate and
the blood coagulation parameters, aPTT and ECT, were
analysed in order to evaluate the relationship between
dabigatran plasma concentrations and the degree of anti-
coagulation achieved in patients following total hip
replacement surgery. Maximum prolongation of both
aPTT and ECT occurred approximately 2 h after oral
drug administration and displayed an increase with ris-
ing doses of dabigatran etexilate. Maximum aPTT, mea-
sured at steady state, was 1.9-fold longer than baseline
levels (predose aPTT), while maximum ECT was pro-
longed by approximately fivefold.
The objective of the population modelling of aPTT/
ECT data from the study was to provide PK–PD mod-
els for both blood coagulation parameters. An in-depth
analysis of the PD response to dabigatran etexilate was
considered important to enable appropriate dose selec-
tion for subsequent Phase III clinical trials evaluating
the benefits of dabigatran in the prevention of VTE
after orthopaedic surgery. However, further investiga-
Table 3
Mean estimates, standard error, interindividual variability and descriptions of component parameters in the ecarin clotting time 
(ECT) concentration–response model based on data from the BISTRO I patient population
Parameter
Parameter
estimate RSE (%)* IIV (%)†
RSE of
IIV (%)* Description
BAS0 (s) 28.0 0.49 8.2‡ 8.98§ Baseline ECT at time 0 on the day of surgery
SLO0 (s ng−1 ml−1) 0.377 2.18 13.7‡ 13.76§ Initial slope value (SLOP) at time 0, on the day of 
surgery
SLOF (s ng−1 ml−1) 0.268 1.49 NE NE Final slope value at time infinity
KM (h−1) 0.617 13.55 NE NE Constant describing the exponential rate of 
decline in the slope from 0 h to the final value
EMBA 0.175 6.46 NE NE Constant describing the maximum decrease in 
baseline ECT over time
ET50 (days) 2.86 13.50 NE NE Time point at which the baseline ECT has declined 
to half the EMBA
Residual error 6.63* 6.83 NE NE Proportional error reported as coefficient of 
variation (CV %)
*RSE, Residual standard error. Percentage standard error for the parameter estimates was calculated according to percentage
RSE: 100% · SE/parameter estimate. †IIV, Interindividual variability. Estimates of variance components (ω and σ) were converted
into standard deviations by taking their square root. These are reported as coefficients of variation (CV %) after multiplying
them by 100. ‡Interindividual variability is based on values for E0 and SLOP rather than BAS0 (initial Emax at time 0) or SLO0
(initial SLOP at time 0). §Percent SE is given on the variance scale; NE, not estimated.
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tions of the relationship between aPTT and ECT pro-
longation and clinical outcome data, i.e. incidence of
VTE and bleeding events, are required for dosing
recommendations.
In contrast to warfarin, dabigatran etexilate is an oral
anticoagulant that is not metabolized by the cytochrome
P450 isoenzymes (CYP450). In vitro studies indicated
that dabigatran does not induce or inhibit CYP450
enzymes. In a Phase I clinical trial the absence of any
relevant drug–food interactions has been shown [8].
Therefore, its PD response is likely to be more predict-
able than that of warfarin and dabigatran etexilate might
be administered without the requirement for coagula-
tion monitoring. An assessment of the status of antico-
agulation may be appreciated for the safe and effective
management of patients undergoing emergency surgery
and those who experience bleeding events following
anticoagulation. The aPTT and ECT models developed
in this study provide an insight into the PD charact-
eristics of dabigatran, contributing to rational dose
selection for this new therapeutic agent that may be
adopted to enable its effective application in thrombosis
prophylaxis.
aPTT model
Prolongation of aPTT in orthopaedic patients following
the administration of dabigatran etexilate was character-
ized by a curvilinear increase, which was best described
by a combined Emax-type/linear model. This model pro-
vided a significantly better fit than a power model gen-
erated for aPTT data from healthy volunteers in Phase
I studies of the drug [6].
Similar nonlinear aPTT relationships have recently
been shown for other DTIs. Inogatran displayed a cur-
vilinear aPTT correlation, which has also been modelled
using a combined Emax-type/linear model [14]. The addi-
tion of melagatran to pooled human plasma prolonged
the aPTT in a concentration-dependent manner but was
also associated with a nonlinear concentration–effect
response that was flattened at higher concentrations
[16]. The model used to describe the PK–PD character-
istics of melagatran employed linear least squares
regression of the aPTT ratios vs. the square root of the
melagatran plasma concentrations. The authors con-
cluded that, due to the low sensitivity of the assay, aPTT
may be more suitable to provide a qualitative indication
of anticoagulant activity than for precise quantification
of the anticoagulant effect. The same conclusion might
be drawn regarding the aPTT response to dabigatran.
The lack of standardization of aPTT assays and the use
of a large variety of assay reagents with different sensi-
tivities between laboratories [29], in conjunction with
the low precision and sensitivity of this assay, prohibit
its use as a quantitative tool for monitoring DTIs.
In the current study, population PD modelling of the
aPTT response in patients undergoing hip replacement
surgery who received treatment with dabigatran etexi-
late for VTE prophylaxis provided insight into the time
course of the aPTT response. Sensitivity and baseline
aPTT were higher shortly after surgery than at later time
points (e.g. 6–10 days after treatment). The PD model
adequately describes the varying sensitivity of aPTT
over time and provides estimates of the magnitude of
these effects. The time to 50% of the maximum aPTT
value (ET50) was approximately 1.6 days for both Emax
and baseline aPTT, with a maximum decline of approx-
imately 46% for Emax and 10% for baseline aPTT. The
clinical relevance of this observation remains to be elu-
cidated; however, it may be explained by dilution and
draining effects caused by transfusions and/or perioper-
ative bleeding. The higher sensitivity of the aPTT
response early after surgery may compensate for the
approximately 12% lower bioavailability of dabigatran
following oral administration on day of surgery com-
pared with drug exposure at steady state [8].
ECT model
The relationship between dabigatran plasma concentra-
tions and ECT in the current study was described by a
linear function over the full range of concentrations.
Even at very high concentrations, no flattening of the
ECT response was observed. The sensitivity of ECT to
dabigatran was greater than that of aPTT, with a maxi-
mum ECT prolongation at the upper end of the clini-
cally relevant dose range of approximately fivefold,
compared with the twofold maximum prolongation of
aPTT. The precision of the ECT assay was also superior
to that of aPTT, as indicated by low interindividual
variability (CV %) in ECT values at baseline (8%) and
in the slope of the line of regression (14%). These find-
ings suggest that, compared with aPTT, the ECT assay
may provide a more accurate quantitative measure of
anticoagulation in patients receiving a DTI. However,
the sensitivity of the ECT assay varies between labora-
tories, depending on the ecarin reagent used, and a stan-
dardized ECT test is not yet available for routine use in
clinical laboratories.
As with aPTT, the mean population values for ECT
at baseline and slope changed with time after surgery.
Baseline ECT was 28 s and declined by approximately
12.6% within 1 week after surgery. The slope of the
plasma concentration–ECT relationship decreased from
0.38 s ng−1 ml−1 at the time of first administration to
0.27 s ng−1 ml−1 at time infinity, indicating higher sensi-
K-H. Liesenfeld et al. 
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tivity early after surgery. As with aPTT, the clinical
significance of these effects remains unclear.
Conclusions
The PK–PD relationship between dabigatran plasma
concentrations and the blood coagulation parameters,
aPTT and ECT, has been fully characterized in ortho-
paedic patients receiving oral dabigatran etexilate for
thromboprophylaxis following hip replacement surgery.
As with the other DTIs, the aPTT response was nonlin-
ear, less precise and of relatively low sensitivity. In
contrast, the PK–PD relationship between dabigatran
and ECT remained linear over the full plasma concen-
tration range. Compared with aPTT, the ECT assay pro-
vided a greater degree of sensitivity and accuracy,
enabling more precise description of the anticoagulant
effect of dabigatran.
This is the first report to demonstrate that both aPTT
and ECT responses in orthopaedic patients vary with
time after surgery. aPTT and ECT responses are highest
immediately after surgery and both decline with time.
The mechanism underlying this finding remains unclear;
however, perioperative effects, such as the transfusion
of large volumes of fluids, may contribute to this effect.
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